NewswireToday - /newswire/ -
Basel, Switzerland, 2008/11/05 - Genedata, a leading provider of in-silico solutions for pharmaceutical R&D and related life sciences, today announced a High-Throughput Screening collaboration with the Drug Discovery Center, Genome Research Institute (GRI), University of Cincinnati.
Genedata Screener®, an open and scalable enterprise solution for high throughput screening (HTS) and high content screening (HCS), will be completely integrated into the center’s HTS workflows.
The Drug Discovery Center is working on molecular probes for application in the pharmaceutical and biotech industries and needed a software solution to manage and analyze their small molecule screening campaigns. The Screener platform combines enterprise-wide assay data management with high-performance processing workflows and flexible analysis tools to rapidly analyze, integrate and manage all assay data, independent of instrumentation, technology, volume or location.
“The Screener system from Genedata matched our screening and analysis workflows and is easy to use. Users can start working with Screener on the fly and need very little additional IT support,” explained Dr. Sandra Nelson, Director of High Throughput Screening and Research Associate Professor at the University of Cincinnati. “Another key feature for us is the automated quality control which has reduced analysis and review time from days to mere hours per screen.“
Dr. Othmar Pfannes, CEO of Genedata, stated, “Genedata is excited to be working with the Drug Discovery Center to help forward their innovative research in screening of small molecules and cell-based assays. We are pleased to continue to provide tailored solutions for a broad range of applications including academic research projects.”
About The Drug Discovery Center
The Drug Discovery Center at the GRI is dedicated to the discovery and early development of novel and commercially viable therapeutic applications. The Drug Discovery Center offers academic and industry scientists access to computational biology, high-throughput screening (HTS), medicinal chemistry and a 250,000 pharma-quality small molecule compound library. The Drug Discovery Center is managed by experienced pharmaceutical industry trained managers and staff. Strategically placed at the intersection of established academic and industrial entities, the Drug Discovery Center is designed to fulfill both scientific and commercial objectives.
Genedata (genedata.com) develops and globally markets sophisticated computational solutions for drug discovery and related research processes in the life sciences. Genedata’s solutions enable scientists to process, integrate, analyze, and manage large and complex experimental data sets generated by high-throughput technologies. Our solutions include Genedata Phylosopher® for target discovery and integrative biological data management, Genedata Screener® for automated high throughput screening and high content screening, and Genedata Expressionist® for biomarker discovery and personalized medicine. Founded in 1997, Genedata is privately held, with headquarters in Basel, Switzerland, and offices in Boston & San Francisco, USA, Konstanz & Munich, Germany and Tokyo, Japan.